Trial Profile

A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Mar 2023 According to a Simcere Pharmaceutical Group media release, Pembrolizumab drug has been added in this study.
14 Mar 2023 According to a Simcere Pharmaceutical Group media release, company announced that Simcere Zaiming, an innovative oncology pharmaceutical company of Simcere has entered into a clinical collaboration agreement with MSD to evaluate the combination of SIM0235 and KEYTRUDA (pembrolizumab), in patients with advanced solid tumors and cutaneous T-cell lymphoma (CTCL).
01 Nov 2022 According to a Simcere Pharmaceutical Group media release, first patient has been dosed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com